Senthil Damodaran

home / authors / senthil-damodaran

Articles

Futibatinib/Fulvestrant AEs Remains Consistent in Advanced FGFR+ Breast Cancer

Futibatinib/Fulvestrant AEs Remains Consistent in Advanced FGFR+ Breast Cancer

Senthil Damodaran;Rina Lokaj
January 2nd 2024
Potential Combination Regimens With Fulvestrant in HR+/HER2− Breast Cancer

Potential Combination Regimens With Fulvestrant in HR+/HER2− Breast Cancer

Senthil Damodaran;Rina Lokaj
December 30th 2023
Final Results Show PFS Benefit With Futibatinib for HR+ HER2– Breast Cancer

Final Results Show PFS Benefit With Futibatinib for HR+ HER2– Breast Cancer

Rina Lokaj;Senthil Damodaran
December 29th 2023
9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

Aditya Bardia, MD, MPH;Ian E. Krop;Dejan Juric;Takahiro Kogawa;Erika P. Hamilton, MD;Alexander Spira, MD, PhD, FACP;Toru Mukohara;Takuya Tsunoda;Senthil Damodaran;Funda Meric-Bernstam, MD
April 28th 2023
37 Open-Label, Phase 2, Multicenter Study of Lasofoxifene (LAS) Combined With Abemaciclib (Abema) for Treating Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation After Progression on Prior Therapies

37 Open-Label, Phase 2, Multicenter Study of Lasofoxifene (LAS) Combined With Abemaciclib (Abema) for Treating Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation After Progression on Prior Therapies

David J. Portman;Senthil Damodaran;Paul V. Plourde;Halle C. F. Moore, MD;Ian C. Anderson
April 27th 2023

Latest Updated Articles

OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
45-Year-Old Female With Gross Hematuria Post Partial Nephrectomy
Published: March 1st 2018 | Updated: July 27th 2024
45-Year-Old Female With Gross Hematuria Post Partial Nephrectomy
Neonate With a Soft, Yellowish-Colored Plaque on the Temple
Published: July 16th 2011 | Updated: July 27th 2024
Neonate With a Soft, Yellowish-Colored Plaque on the Temple
A 54-Year-Old Woman Notes the Abundant Development of Nonpigmented Hair on Her Ears and Nose
Published: May 12th 2012 | Updated: July 27th 2024
A 54-Year-Old Woman Notes the Abundant Development of Nonpigmented Hair on Her Ears and Nose
Patient With History of COPD Presents With Abdominal Pain
Published: December 1st 2016 | Updated: July 27th 2024
Patient With History of COPD Presents With Abdominal Pain